Advanced workflow automation and scalable image analysis in spatial biology

ZEISS and Concept Life Sciences announce partnership.

The business coach: “We need to learn from our mistakes”

The past year has been challenging for many biotech companies, with several comapanies facing financial stress and bankruptcy. To understand how entrepreneurs c...

An organ seldom in the spotlight – but utterly vital

The kidneys consist of more than 40 types of cells and have more functions in the body than most people know. Julie Williams leads AstraZeneca’s work in preclin...

Novartis storsatsar på RNA-terapier – köper miljardbolag

Novartis förvärvar amerikanska Avidity Biosciences för 12 miljarder dollar, motsvarande 113 miljarder kronor. Köpet stärker bolagets position inom sällsynta mus...

Osäkerhet kring IVF-reform i USA – svenskt bolag backar

Vita huset backar från Donald Trumps vallöfte om att öka tillgången till fertilitetsbehandlingar. Svenskt medicinteknikbolaget faller ytterligare efter beskedet.

Meet us at Control 2025

Innovations that drive efficiency.

Europeiska läkemedelsaktier rasar efter Trumps tullhot

Europeiska läkemedelsbolag faller kraftigt efter att USA:s president Donald Trump flaggat för att stora tullhöjningar är på gång mot branschen.

How to avoid measurement inaccuracies due to wear

Expert tip from ZEISS.

Billion-Dollar Deal Sends BioArctic Soaring

Swedish Alzheimer-focused company BioArctic has entered into a licensing collaboration with Novartis regarding a technology aimed at enhancing efficient drug de...

ZEISS at EMO Hannover 2025

Experience some of the most exciting highlights from our ZEISS product portfolio.

Cancer researcher: “We can do better and reduce suffering”

Lund University researcher Catharina Hagerling is developing innovative methods to understand metastatic cancer, aiming to create more targeted treatments for p...

Organize and Manage Digital Classrooms

Create engaging lessons with ZEISS Labscope Teacher.

ZEISS Quality Innovations at CONTROL

May 6-9, 2025 in Stuttgart.

Lovande resultat för Lillys fetmapiller – skapar börsvågor

Eli Lillys viktminskningspiller överträffar förväntningarna i en fas III-studie och visar resultat i nivå med injicerbara läkemedel som Ozempic. Nyheten fick ak...

Gelhype, börsras och fetmastudie – här är nyheterna som lästes mest i oktober

En ny studie pekar ut varför många patienter avbryter behandling med den nya sortens läkemedel mot obesitas. Det är den nyhet som har lästs mest den här månaden.

Health politician Lina Nordquist: ”I find it hard to be idle”

She is the pharmacist and researcher who grew tired of the breakthroughs that never materialised and knowledge that never seemed to reach patients, so she decid...

Anocca raises SEK 440 million ahead of clinical cancer trial

Swedish cell therapy biotech Anocca has successfully raised SEK 440 million in a new funding round to support upcoming clinical trials in pancreatic cancer.

Optimize Courier SUPPLIERS (DISTRIBUTORS)

Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.

Sanofi backar efter besvikelse i KOL-studie

Blandade resultat för KOL-behandlingen Itepekimab i två fas III-studier fick Sanofis och Regenerons aktier att backa ordentligt på fredagen.

ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions

ZEISS Medical Technology will showcase new ophthalmic innovations and market milestones at ESCRS 2025 in Copenhagen.

ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment

Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care.

Roche joins Medicon Village

Roche and Medicon Village Innovation have signed an agreement for deeper collaboration. “The fact that Roche is now becoming part of this environment further st...

Wegovy approved in the U.S. for treatment of liver disease

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Novo Nordisk’s drug Wegovy to treat the serious liver condition known as MASH. ...